Dipeptidyl-Peptidase 4 and Attractin Expression is Increased in Circulating Blood Monocytes of Obese Human Subjects

Abstract

Dipeptidyl-peptidase (DPP)-4, which catalizes the degradation of the insulinotropic incretin glucagon-like-peptide (GLP)-1, and the DPP-4 like enzyme attractin are involved in activation of T-lymphocytes and monocytes. Recently, it has been demonstrated, that the risk for certain infections is increased in type 2 diabetic patients under DPP-4 inhibitor treatment. The aim of the present study was to examine the expression of DPP-4 and attractin in circulating blood monocytes of obese and type 2 diabetic subjects. Monocytes were isolated by CD14-antibody based magnetic cell sorting from blood samples of 17 lean controls, 20 obese, non-diabetic subjects and 19 obese patients with type 2 diabetes. FACS analysis was performed to test purity of the cell preparations. Expression was measured by multiplex RT-PCR on RNA-level. DPP-4 and attractin were detectable in human circulating monocytes with attractin being expressed at higher levels compared to DPP-4. Both enzymes were significantly higher expressed in circulating blood monocytes of obese subjects compared to lean controls. In contrast, type 2 diabetes did not significantly affect expression levels. Finally, neither DPP-4 nor attractin expression was altered by sitagliptin or insulin treatment. In conclusion, our data demonstrate, that expressions of DPP-4 and attractin in circulating blood monocytes of human subjects are influenced by metabolic abnormalities with obesity being an important factor.

Key words

diabetes - autoimmunity - incretins - immune system

References

• 1 Ahrén B, Simonsson E, Larsson H. et al . Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.  Diabetes Care. 2002;  25 69-875
• 2 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.  JAMA. 2007;  298 194-206
• 3 Ban K, Noyan-Ashraf MH, Hoefer J. et al . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.  Circulation. 2008;  117 2340-2350
• 4 Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.  Endocrinology. 1996;  137 2968-2978
• 5 Cybulsky MI, Iiyama K, Li H. et al . A major role for VCAM-1, but not ICAM-1, in early atherosclerosis.  J Clin Invest. 2001;  107 1255-1262
• 6 Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.  Int J Biochem Cell Biol. 2006;  38 831-844
• 7 Farilla L, Bulotta A, Hirshberg B. et al . Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.  Endocrinology. 2003;  144 5149-5158
• 8 Holst JJ, Orskov C. Incretin hormones – an update.  Scand J Clin Lab Invest Suppl. 2001;  234 75-85
• 9 Ishihara H, Maechler P, Gjinovci A. et al . Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells.  Nat Cell Biol. 2003;  5 330-335
• 10 Lambeir AM, Durinx C, Scharpé S. et al . Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.  Crit Rev Clin Lab Sci. 2003;  40 209-294
• 11 Larsen CM, Faulenbach M, Vaag A. et al . Interleukin-1-receptor antagonist in type 2 diabetes mellitus.  N Engl J Med. 2007;  356 1517-1526
• 12 Näslund E, Barkeling B, King N. et al . Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.  Int J Obes Relat Metab Disord. 1999;  23 304-311
• 13 Nauck M, Stöckmann F, Ebert R. et al . Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.  Diabetologia. 1986;  29 46-52
• 14 Nauck MA, Homberger E, Siegel EG. et al . Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.  J Clin Endocrinol Metab. 1986;  63 492-498
• 15 Nauck MA, Kleine N, Orskov C. et al . Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.  Diabetologia. 1993;  36 741-744
• 16 Nauck MA, Niedereichholz U, Ettler R. et al . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.  Am J Physiol. 1997;  273 E981-E988
• 17 Pacheco R, Martinez-Navio JM, Lejeune M. et al . CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.  Proc Natl Acad Sci U S A. 2005;  102 9583-9588
• 18 Perry T, Lahiri DK, Sambamurti K. et al . Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.  J Neurosci Res. 2003;  72 603-612
• 19 Verdich C, Flint A, Gutzwiller JP. et al . A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.  J Clin Endocrinol Metab. 2001;  86 4382-4389
• 20 Vilsbøll T, Agersø H, Krarup T. et al . Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.  J Clin Endocrinol Metab. 2003;  88 220-224
• 21 Wrenger S, Faust J, Friedrich D. et al . Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function.  J Leukoc Biol. 2006;  80 621-629
• 22 Xu G, Stoffers DA, Habener JF. et al . Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.  Diabetes. 1999;  48 2270-2276
• 23 Yamagata S, Tomita K, Sato R. et al . Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model.  Clin Exp Immunol. 2008;  154 295-304
• 24 Zhou J, Wang X, Pineyro MA. et al . Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.  Diabetes. 1999;  48 2358-2366

Correspondence